Gubra AS (CHIX:GUBRAC) Short-Term Debt : kr0.0 Mil (As of Dec. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Gubra AS Short-Term Debt?

Gubra AS's Short-Term Debt for the quarter that ended in Dec. 2024 was kr0.0 Mil.

Gubra AS Short-Term Debt Historical Data

The historical data trend for Gubra AS's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gubra AS Short-Term Debt Chart

Gubra AS Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Short-Term Debt

Get a 7-Day Free Trial

2.14

2.16

Gubra AS Semi-Annual Data
	Dec19	Dec20	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Short-Term Debt	Get a 7-Day Free Trial				-	-	-	-	-

Gubra AS Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Gubra AS Short-Term Debt Related Terms

Thank you for viewing the detailed overview of Gubra AS's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Gubra AS Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gubra AS (CHIX:GUBRAc) » Definitions » Short-Term Debt

Comparable Companies

Traded in Other Exchanges

GUBRA:Denmark PI3:Germany

Address

Horsholm Kongevej 11B, Horsholm, DNK, 2970

Website

https://www.gubra.dk

Gubra AS is a specialized preclinical CRO and biotech company focused on peptide-based drug discovery within metabolic and fibrotic diseases. The company has three segments: Pre-clinical contract research (CRO), which derives maximum revenue; Discovery & Partnerships (D&P) Segment; and Gubra Green Segment. It derives maximum revenue from Pre-clinical contract research (CRO) segment. Geographically, the company operates in Europe, North America and Other regions.

Gubra AS Headlines

No Headlines